6-Day Rally Sends Exicure Stock Up 76%
Exicure (XCUR) stock hit day 6 of a continuous streak of days with gains, with cumulative gains over this period amounting to a 76% return. The company has gained about $19 Mil in value over the last 6 days, with its current market capitalization at about $44 Mil. The stock remains 50.7% below its value at the end of 2024. This compares with year-to-date returns of 16.6% for the S&P 500.
Exicure’s shares have rallied on promising clinical news for its lead asset, burixafor, ahead of its oral presentation at the ASH annual meeting on December 8. Positive Phase 2 data revealed 100% of evaluable multiple myeloma patients met the primary endpoint for stem cell mobilization, touting a rapid, same-day treatment advantage over competitors, fueling optimism for potential Phase 3 trials and pipeline expansion.
What is the point? Momentum often precedes conviction. A multi-day win streak can signal growing investor confidence or spark follow-on buying. Tracking such trends can help you ride the strength, or prepare for a well-timed entry if momentum fades.For quick background, XCUR develops therapies for neurological disorders and hair loss using proprietary spherical nucleic acid technology, collaborating with AbbVie to develop SNA-based hair loss treatments.
Comparing XCUR Stock Returns With The S&P 500
The following table summarizes the return for XCUR stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | XCUR | S&P 500 |
|---|---|---|
| 1D | 21.2% | 0.1% |
| 6D (Current Streak) | 76.4% | 1.3% |
| 1M (21D) | 59.3% | 1.3% |
| 3M (63D) | 41.9% | 5.8% |
| YTD 2025 | -50.7% | 16.6% |
| 2024 | 371.1% | 23.3% |
| 2023 | -49.5% | 24.2% |
| 2022 | -81.0% | -19.4% |
Gains and Losses Streaks: S&P 500 Constituents
There are currently 87 S&P constituents with 3 days or more of consecutive gains and 71 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 63 | 17 |
| 4D | 2 | 37 |
| 5D | 5 | 11 |
| 6D | 4 | 6 |
| 7D or more | 13 | 0 |
| Total >=3 D | 87 | 71 |
Key Financials for Exicure (XCUR)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $0 | $0.5 Mil |
| Operating Income | $-13.1 Mil | $-4.9 Mil |
| Net Income | $-16.9 Mil | $-9.7 Mil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ1 | 2025 FQ2 |
|---|---|---|
| Revenues | $0 | $0 |
| Operating Income | $-3.0 Mil | $-2.4 Mil |
| Net Income | $3.0 Mil | $-2.6 Mil |
While XCUR stock looks attractive given its winning streak, investing in a single stock without detailed, thorough analysis can be risky. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.